Regeneron COVID-19 Therapeutic, Novavax Vaccine Get BARDA Funding To Boost Manufacturing
Executive Summary
US government to own doses of Regeneron's investigational cocktail antibody REGN-COV2 manufactured under a $450m contract and 100 million doses of Novavax's investigational vaccine under a $1.6bn agreement.
You may also be interested in...
Regeneron COVID-19 Cocktail’s Flame To Burn Brightly But Unclear For How Long
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.
Regeneron Pressed About Pending COVID-19 Antibody EUA
CEO Len Schleifer said he does not know the timeline for when the US FDA could authorize REGN-COV2 but expects to hear from the agency soon.
Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.